Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
about
Effects of bevacizumab on endoplasmic reticulum stress in hypoxic retinal pigment epithelial cells.Role of intravitreal bevacizumab in adult onset Coats' disease.Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbitsTransfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheepA prospective, randomized comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab (avastin) in diffuse diabetic macular edema.The effect of intravitreal bevacizumab (Avastin) on ocular pulse amplitude in neovascular age-related macular degeneration.Comparison of intravitreal bevacizumab with macular photocoagulation for treatment of diabetic macular edema: a systemic review and Meta-analysis.Pharmacokinetics of intravitreal bevacizumab (AvastinĀ®) in rabbitsIntra-Laboratory Pre-Validation of a Human Cell Based in vitro Angiogenesis Assay for Testing Angiogenesis Modulators.Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumabOmega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degenerationComparison of intravitreal bevacizumab and triamcinolone acetonide theraphies for diffuse diabetic macular edema.Intravitreal bevacizumab as an adjunct to vitrectomy in advanced Eales' disease.Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade.Expression and role of VEGF--a in the ciliary body.The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healingDifferential regulation of angiogenesis using degradable VEGF-binding microspheres.Daily Optical Coherence Tomography Examinations after First Antivascular Endothelial Growth Factor Injections: An Interventional Case Series.Intravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis.Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls.Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals.Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy.Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF.Trends in proteomic analysis of human vitreous humor samples.The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model.An anti-angiogenic reverse thermal gel as a drug-delivery system for age-related wet macular degeneration.Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.Absence of collagen XVIII in mice causes age-related insufficiency in retinal pigment epithelium proteostasis.Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy.Histological findings of uveal capillaries in rabbit eyes after multiple intravitreal injections of bevacizumab.Therapeutic efficacy of bevacizumab for age-related macular degeneration: what are the implications of CATT for routine management?Comparative Study of In Situ Loaded Antibody and PEG-Fab NIPAAM Gels.Clinical pharmacology of intravitreal anti-VEGF drugs.Safe dose of intravitreal imatinib and its effect on laser-induced choroidal neovascularization: a rat-model experiment.Safety of submacular suprachoroidal drug administration via a microcatheter: retrospective analysis of European treatment results.Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration.Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment.Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema.
P2860
Q33773175-9363BA5C-5024-4D49-A522-E85E88A2A41FQ33855989-D9C7B383-CF4B-4B27-8CAC-78218A86AAF5Q33911625-18E47C66-B784-4C34-A9E2-DC3D33F71C76Q33912465-EDEE705D-BEF4-4185-8C9D-ADF120F01195Q34107543-7D28E97D-348A-4B4C-A1F0-85AF4A5A0300Q34620930-F89E3E31-9E3B-4A36-AB5C-30F0420994EFQ34735711-8AC70E35-EC23-4542-B312-1DCD17C3565FQ35015882-23259113-30F7-492E-8D29-B3165C3458A9Q35100891-AF44DA43-BD48-4D22-85B0-2026B6EC5E1EQ35226694-9F5E7D24-63BB-4EE4-9C7C-7B19D83400B7Q35316532-ECED4DD0-2AB1-48EF-A2C1-BCA36D28FB11Q35691932-6F98937D-2BD3-4EEE-BCD1-9D73256500E6Q35935978-9711C839-3EDA-47DD-B9BF-467EB5AEF38CQ36154521-344B85FB-9652-4479-81B1-0EDD4002042EQ36383625-A5B86536-1416-4172-B6DB-44B72A866363Q36574090-4531197A-95FF-440A-A8A0-CDA07B829100Q36899777-83497790-23CA-40C5-9DA8-C0646E61BFA4Q36914264-3EFE74D4-52AF-4F0A-BE55-6C7D1662D83FQ37126900-D8B1AB6A-5239-4634-9810-4530803C85E8Q37133086-A5386763-746A-4AB1-ACD9-CA31AC9A386DQ37455178-58DACEA6-6EDF-4E0E-8173-B47D9F99D71BQ37549985-609C6ACF-51B9-4F3E-9510-060187FAD26AQ37882685-2340022A-1457-4295-AAD1-ED647D977FDEQ38168825-D973433D-ADCC-4541-B7CC-428160035C7AQ38183850-5D99E63D-DD22-44BA-BA0D-BCCCE430DE26Q38211623-5F043F7B-C571-4E5E-86CA-503DF4E01EE9Q38258893-3AA5CAFE-112C-40A8-9C8A-100E2F5FB936Q41970943-9528880A-581A-4FC0-B604-620D182904A8Q42414491-89CE2D30-452E-4139-9F20-1F5C3F8F728FQ42492505-A69A80A5-E513-4936-B9DC-2479A5EE08DBQ42725451-2378E795-2051-4070-84E3-AC8EEF1A760EQ45759035-EDA8B707-3CB5-4A29-B0E5-4C0B0688AD9AQ46526244-33CD27A6-6416-424C-AFAF-CC26C3576E9AQ47330134-FC520EF9-340E-4273-884D-584169807124Q48109878-3565AA85-8944-437A-9AA8-7C98BABD7870Q51099974-3A239A41-CD48-4CBF-B76D-9B50A9CE7CAFQ52889544-3D149BB1-940E-42CC-B07C-CFC31C3AA9D4Q53315137-2BAB92DE-8554-48AD-A181-4B182AE94A99Q53577573-E3A55C97-00F9-4307-9CA5-79ED8EEF7730Q53611312-F0D935FC-EFDC-4A95-A7FF-F0FF9B8E999F
P2860
Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
description
2008 nĆ® lÅ«n-bĆ»n
@nan
2008幓ć®č«ę
@ja
2008幓å¦ęÆęē«
@wuu
2008幓å¦ęÆęē«
@zh
2008幓å¦ęÆęē«
@zh-cn
2008幓å¦ęÆęē«
@zh-hans
2008幓å¦ęÆęē«
@zh-my
2008幓å¦ęÆęē«
@zh-sg
2008幓åøč”ęē«
@yue
2008幓åøč”ęē«
@zh-hant
name
Vitreous levels of bevacizumab ...... choroidal neovascularization.
@en
Vitreous levels of bevacizumab ...... choroidal neovascularization.
@nl
type
label
Vitreous levels of bevacizumab ...... choroidal neovascularization.
@en
Vitreous levels of bevacizumab ...... choroidal neovascularization.
@nl
prefLabel
Vitreous levels of bevacizumab ...... choroidal neovascularization.
@en
Vitreous levels of bevacizumab ...... choroidal neovascularization.
@nl
P2093
P1433
P1476
Vitreous levels of bevacizumab ...... choroidal neovascularization.
@en
P2093
Focke Ziemssen
Nicole Schneiderhan-Marra
Olcay Tatar
Peter Szurman
Salvatore Grisanti
Sigrid Henke-Fahle
TĆ¼bingen Bevacizumab Study Group
P304
1750-5, 1755.e1
P356
10.1016/J.OPHTHA.2008.04.023
P577
2008-08-16T00:00:00Z